Ocular Therapeutix (OCUL) Return on Capital Employed (2014 - 2026)
Ocular Therapeutix (OCUL) recorded quarterly Return on Capital Employed of 41.44% in Q1 2026, up 14.26% quarter-over-quarter from 48.33% in Q4 2025, and up 1036.0% on a YoY basis from 3.65% in Q1 2025.
Ocular Therapeutix (OCUL) Return on Capital Employed (2014 - 2026) Analysis & Trends
Ocular Therapeutix's Return on Capital Employed history runs 13 years deep, the most recent figure standing at 41.44% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 1036.0% year-over-year to 41.44%; the TTM figure through Mar 2026 stood at 41.44% (up 1036.0% YoY), while the FY2025 annual figure was 46.38%, up 839.0% from the prior year.
- Return on Capital Employed was 41.44% for Q1 2026 at Ocular Therapeutix, up from 48.33% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 22.98% in Q2 2024 to a low of 90.15% in Q2 2023.
- Historically, Return on Capital Employed has averaged 52.23% across 5 years, with a median of 48.84% in 2022.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed plunged 4131 bps in 2023, then jumped 6716 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 64.19% in 2022, then advanced by 26 bps to 47.81% in 2023, then rose by 17 bps to 39.69% in 2024, then fell by 22 bps to 48.33% in 2025, then advanced by 14 bps to 41.44% in 2026.
- The last three Return on Capital Employed figures came in at 41.44% (Q1 2026), 48.33% (Q4 2025), and 65.69% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -107.40% |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -50.43% |
| 10 | Ocular Therapeutix | 2.01 Bn | 2.01 Bn | 9.46 Mn | -41.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -41.44% |
| Dec 31, 2025 | -48.33% |
| Sep 30, 2025 | -65.69% |
| Jun 30, 2025 | -59.15% |
| Mar 31, 2025 | -51.80% |
| Dec 31, 2024 | -39.69% |
| Sep 30, 2024 | -30.22% |
| Jun 30, 2024 | -22.98% |
| Mar 31, 2024 | -24.64% |
| Dec 31, 2023 | -47.81% |
| Sep 30, 2023 | -76.06% |
| Jun 30, 2023 | -90.15% |
| Mar 31, 2023 | -76.33% |
| Dec 31, 2022 | -64.19% |
| Sep 30, 2022 | -56.64% |
| Jun 30, 2022 | -48.84% |
| Mar 31, 2022 | -43.90% |
| Dec 31, 2021 | -42.19% |
| Sep 30, 2021 | -37.34% |
| Jun 30, 2021 | -31.96% |